The Fort Worth Press - Medical Care Technologies Inc. (OTCID:MDCE) Delivers Stronger Melanoma Scan Beta Readout on Expanded Human-Submitted Dataset

USD -
AED 3.673008
AFN 65.000388
ALL 81.123148
AMD 360.499098
ANG 1.789785
AOA 918.000573
ARS 1545.153474
AUD 1.42573
AWG 1.8
AZN 1.703383
BAM 1.744435
BBD 2.013263
BDT 124.343874
BGN 1.747831
BHD 0.377375
BIF 3005.17765
BMD 1
BND 1.278581
BOB 12.140484
BRL 5.438198
BSD 0.999585
BTN 94.811201
BWP 13.808328
BYN 2.953267
BYR 19600
BZD 2.01032
CAD 1.397865
CDF 2314.999949
CHF 0.818165
CLF 0.024845
CLP 977.539697
CNY 6.661102
CNH 6.646095
COP 3211.12
CRC 454.527211
CUC 1
CUP 23.989333
CVE 98.348593
CZK 21.710221
DJF 177.71951
DKK 6.669295
DOP 60.740391
DZD 135.769837
EGP 55.347613
ERN 15
ETB 162.433359
EUR 0.89241
FJD 2.255897
FKP 0.746765
GBP 0.745305
GEL 2.603468
GGP 0.746765
GHS 11.650194
GIP 0.746765
GMD 73.999981
GNF 8847.047491
GTQ 7.642051
GYD 209.539525
HKD 7.846535
HNL 26.869372
HRK 6.76901
HTG 131.015506
HUF 324.890979
IDR 18104
ILS 3.14045
IMP 0.746765
INR 94.68585
IQD 1515.298819
IRR 1868415.000233
ISK 121.560427
JEP 0.746765
JMD 158.843703
JOD 0.709048
JPY 157.796502
KES 129.939665
KGS 87.449799
KHR 4088.71367
KMF 440.999789
KPW 899.999961
KRW 1344.05006
KWD 0.31134
KYD 0.832995
KZT 452.368741
LAK 22506.053971
LBP 89514.01494
LKR 332.306128
LRD 169.921466
LSL 16.636267
LTL 2.95274
LVL 0.60489
LYD 6.414756
MAD 9.828437
MDL 18.057593
MGA 4514.054577
MKD 54.922696
MMK 2099.693878
MNT 3599.326016
MOP 8.078026
MRU 40.503405
MUR 47.319961
MVR 15.449534
MWK 1733.348199
MXN 18.54454
MYR 4.071701
MZN 63.910175
NAD 16.636267
NGN 1344.509612
NIO 36.783168
NOK 9.2871
NPR 151.697565
NZD 1.77704
OMR 0.384522
PAB 0.999799
PEN 3.467019
PGK 4.482837
PHP 63.334501
PKR 276.504083
PLN 3.9413
PYG 5917.059487
QAR 3.653878
RON 4.762008
RSD 104.930981
RUB 81.250045
RWF 1478.412502
SAR 3.764439
SBD 8.058206
SCR 13.832645
SDG 601.502778
SEK 9.77118
SGD 1.278615
SHP 0.748335
SLE 22.916689
SLL 20969.504398
SOS 571.280766
SRD 37.579505
STD 20697.981008
STN 21.85227
SVC 8.746259
SYP 13001.999685
SZL 16.630915
THB 33.692963
TJS 9.191303
TMT 3.5
TND 2.987517
TOP 2.40776
TRY 49.969601
TTD 6.761717
TWD 32.594499
TZS 2645.00802
UAH 45.650373
UGX 4277.693292
UYU 40.190338
UZS 11944.718217
VES 887.479798
VND 25764
VUV 118.915185
WST 2.776217
XAF 585.382302
XAG 0.019623
XAU 0.000252232255
XCD 2.70255
XCG 1.80143
XDR 0.707052
XOF 585.382302
XPF 106.371498
YER 236.202866
ZAR 16.56895
ZMK 9001.206005
ZMW 20.242167
ZWL 321.999592
SSP 5745.217636
MXV 2.088469
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Medical Care Technologies Inc. (OTCID:MDCE) Delivers Stronger Melanoma Scan Beta Readout on Expanded Human-Submitted Dataset
Medical Care Technologies Inc. (OTCID:MDCE) Delivers Stronger Melanoma Scan Beta Readout on Expanded Human-Submitted Dataset

Medical Care Technologies Inc. (OTCID:MDCE) Delivers Stronger Melanoma Scan Beta Readout on Expanded Human-Submitted Dataset

Expanded Human-Submitted Image Review Shows Image-Quality Pass Rate of 86%, Body-Map Registration of 89% and Change-Over-Time Alignment of 91%

Text size:

MESA, AZ / ACCESS Newswire / November 2, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that updated internal evaluation results for MDCE Melanoma Scan Beta have been posted on the Company's corporate website.

The full technical summary is available at https://www.medicalcaretechnologies.com.

This release fulfills the Company's October 20 announcement that next-round results on the expanded human-submitted dataset would be published. The evaluation covers the same three technical layers previously described:

  • Image intake and quality scoring - 86% of newly submitted user photographs met the internal usability threshold and advanced to further processing (held-out samples were primarily limited by extreme blur, severe underexposure, or incomplete framing).
  • Body-map registration - 89% of usable images were successfully placed on the interactive body map with sufficient landmark consistency to support later retrieval of the same skin area.
  • Change-over-time comparison - 91% of paired sequential images of a previously mapped area achieved alignment sufficient for side-by-side visual review under the Company's internal protocol.

These figures are drawn from the larger set of human-submitted images collected after the September 29 first-pass results. The first pass had confirmed that real-world photographs could move through the three layers. The current readout reflects continued testing against lighting, device, distance, angle, and compression variables that public archives (HAM10000, ISIC, TCIA) do not fully represent.

Sample internal metrics from the expanded set (controlled sequential captures):

LayerMetricResultNotes
Image qualityUsability pass rate86%Above typical 75-82% range reported for unconstrained smartphone skin images in published consumer-capture studies
Body-mapSuccessful registration89%Landmark consistency sufficient for re-identification of mapped area
Sequential comparisonAlignment completion91%Paired images suitable for visual change review
Overall workflowEnd-to-end completion84%Percentage of submissions that completed all three layers without manual intervention

MDCE Melanoma Scan Beta remains in beta-stage development. It has not received regulatory clearance and is not intended to treat, cure, or prevent any disease or medical condition. It is not a substitute for professional medical advice, screening, or evaluation by a qualified healthcare provider. The results describe internal technical evaluation of image handling, mapping, and comparison only.

"The expanded set produced higher usability and registration numbers than the first pass," said Marshall Perkins, CEO of Medical Care Technologies. "These are internal technical results on photographs people actually take. Intake remains open so we can keep widening the test set."

Volunteer participation is not a clinical diagnosis program and is not a clinical efficacy trial. Any concern about a skin change should be reviewed by a licensed clinician.

About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTCID:MDCE) is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning health, wellness, nutrition, lifestyle, and enterprise imaging analysis solutions. Visit: https://www.medicalcaretechnologies.com

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions, and actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update these statements except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.

Contact Information:
Medical Care Technologies Inc.
1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204
Phone: +1 (480) 645-0750
Email: [email protected]
Website: https://www.medicalcaretechnologies.com

SOURCE: Medical Care Technologies Inc.



View the original press release on ACCESS Newswire

D.Ford--TFWP